Users of this system, can login to view this document.
Login
Enter the following information to request a copy of the document from the responsible person.
RE: Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with 131-I-metaiodobenzylguanidine. Huibregtse K et al. European Journal of Cancer 2016. 66:144–152